Orphan Synergy Europe - Pharma Aktie
| 1,94EUR | -0,19EUR | -9,09% |
WKN DE: A14QXP / ISIN: FR0012127173
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 61 | 67 | 55 | 64 | 64 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,43 | 0,27 | 0,04 | 1,09 | 0,04 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 44 | 37 | 30 | 70 | 32 |
| Summe Anlagevermögen | 57 | 54 | 51 | 54 | 46 |
| Summe Aktiva | 102 | 92 | 82 | 124 | 78 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 54 | 59 | 59 | 60 | 51 |
| Summe Eigenkapital | 48 | 33 | 23 | 63 | 27 |
| Summe Passiva | 102 | 92 | 82 | 124 | 78 |
Adresse
| 22, boulevard Benoni Goullin, 44200 Nantes | |
| Telefon | +33 (2) 28-29-10-10 |
| Internet | http://www.ose-immuno.com |
Management
|
Alexis Peyroles
Independent Director |
|
Aurore Morello
Chief Scientific Officer |
|
Caroline Mary
Director |
|
Jean Jacques Mention
Chief Business Officer |
|
Jonathan M. Cool
Independent Director |
|
Marc Le Bozec
Chief Executive Officer & Director |
|
Markus J. Cappel
Chairman |
|
Pascale Briand
Independent Director |
|
Shihong Nicolaou
Independent Director |
|
Silvia Comis
Chief Clinical & Medical Research Officer |
|
Sonya Montgomery
Chief Development Officer |
|
Thomas Gidoin
Chief Financial Officer & Deputy CEO |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.